Literature DB >> 7812708

Phase II trials of malignant mesothelioma: a commentary and update.

A Krarup-Hansen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7812708     DOI： 10.1016/0169-5002(94)90551-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  2 in total

1.  Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Hasan Senol Coskun; Inci Gulmez; Eyup Ekici; Bunyamin Kaplan; Bulent Eser; Mustafa Ozesmi
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

2.  Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

Authors:  J van Meerbeeck; C Debruyne; N van Zandwijk; P E Postmus; M C Pennucci; F van Breukelen; D Galdermans; H Groen; P Pinson; M van Glabbeke; E van Marck; G Giaccone
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.